HOOKIPA Pharma IncNASDAQ:HOOKNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.7899
- TODAY'S CHANGE (%)0.0382 (5.0818%)
- Bid / Lots0.7840/ 6
- Ask / Lots0.7899/ 1
- Open / Previous Close0.7666 / 0.7517
- Day Range
- 52 Week Range
- Volume251,913
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HOOK |
|---|---|---|
| 09:32 ET | 1033 | 0.7666 |
| 09:34 ET | 100 | 0.774 |
| 09:38 ET | 300 | 0.78 |
| 09:45 ET | 833 | 0.78 |
| 09:48 ET | 9381 | 0.799 |
| 09:50 ET | 6897 | 0.7895 |
| 09:52 ET | 3758 | 0.7924 |
| 09:57 ET | 500 | 0.78903 |
| 10:01 ET | 2276 | 0.78 |
| 10:03 ET | 132 | 0.78534 |
| 10:06 ET | 11792 | 0.7889 |
| 10:08 ET | 400 | 0.7867 |
| 10:12 ET | 7177 | 0.7845 |
| 10:14 ET | 2250 | 0.789 |
| 10:15 ET | 1455 | 0.78 |
| 10:19 ET | 3100 | 0.7854 |
| 10:21 ET | 6008 | 0.79 |
| 10:28 ET | 8869 | 0.7837 |
| 10:30 ET | 500 | 0.784999 |
| 10:35 ET | 200 | 0.79 |
| 10:37 ET | 11367 | 0.781 |
| 10:39 ET | 200 | 0.786384 |
| 10:42 ET | 100 | 0.7865 |
| 10:44 ET | 5678 | 0.786 |
| 10:46 ET | 100 | 0.7884 |
| 10:48 ET | 7368 | 0.781 |
| 10:53 ET | 3578 | 0.781 |
| 11:02 ET | 200 | 0.7811 |
| 11:04 ET | 200 | 0.7847 |
| 11:08 ET | 5423 | 0.781 |
| 11:09 ET | 500 | 0.781 |
| 11:11 ET | 100 | 0.7847 |
| 11:13 ET | 480 | 0.7811 |
| 11:15 ET | 1248 | 0.7884 |
| 11:18 ET | 100 | 0.7847 |
| 11:22 ET | 100 | 0.7842 |
| 11:27 ET | 13032 | 0.7855 |
| 11:29 ET | 1300 | 0.7811 |
| 11:31 ET | 128 | 0.785499 |
| 11:38 ET | 6508 | 0.781 |
| 11:40 ET | 20338 | 0.7777 |
| 11:42 ET | 200 | 0.7777 |
| 11:44 ET | 200 | 0.7777 |
| 11:54 ET | 3024 | 0.77 |
| 11:58 ET | 300 | 0.785 |
| 12:02 ET | 202 | 0.785 |
| 12:03 ET | 12787 | 0.77765 |
| 12:05 ET | 100 | 0.77765 |
| 12:12 ET | 128 | 0.784536 |
| 12:14 ET | 500 | 0.7808 |
| 12:18 ET | 22217 | 0.7762 |
| 12:23 ET | 500 | 0.7762 |
| 12:30 ET | 100 | 0.7794 |
| 12:38 ET | 300 | 0.7765 |
| 12:39 ET | 167 | 0.7794 |
| 12:41 ET | 1000 | 0.782299 |
| 12:56 ET | 150 | 0.78 |
| 01:06 ET | 360 | 0.7765 |
| 01:15 ET | 788 | 0.7765 |
| 01:21 ET | 5658 | 0.7765 |
| 01:42 ET | 975 | 0.78 |
| 01:46 ET | 4493 | 0.775 |
| 01:50 ET | 100 | 0.775 |
| 02:04 ET | 8377 | 0.77965 |
| 02:13 ET | 6952 | 0.7843 |
| 02:18 ET | 4422 | 0.7822 |
| 02:20 ET | 250 | 0.7822 |
| 02:24 ET | 1200 | 0.782311 |
| 02:31 ET | 200 | 0.78 |
| 02:54 ET | 100 | 0.7822 |
| 02:56 ET | 100 | 0.78 |
| 03:05 ET | 363 | 0.7822 |
| 03:07 ET | 1360 | 0.7869 |
| 03:12 ET | 2360 | 0.7899 |
| 03:14 ET | 100 | 0.7899 |
| 03:16 ET | 1200 | 0.785749 |
| 03:18 ET | 7424 | 0.787 |
| 03:20 ET | 500 | 0.7899 |
Yesterday
May 23, 2024
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting, from 5:01PM ET on Thursday May 23, 2024 by Dow Jones
5:01PM ET on Thursday May 23, 2024 by Dow Jones
May 21, 2024
DJ HOOKIPA Pharma Price Target Maintained With a $5.00/Share by RBC Capital, from 1:21PM ET on Tuesday May 21, 2024 by Dow Jones
1:21PM ET on Tuesday May 21, 2024 by Dow Jones
May 9, 2024
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights, from 7:01AM ET on Thursday May 09, 2024 by Dow Jones
7:01AM ET on Thursday May 09, 2024 by Dow Jones*DJ HOOKIPA Pharma 1Q EPS 11c >HOOK, from 7:01AM ET on Thursday May 09, 2024 by Dow Jones
7:01AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
HOOKIPA Pharma Inc | 74.4M | 0.0x | --- |
Company Information
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Contact Information
- Headquarters
- 350 Fifth Avenue, 72Nd Floor, Suite 7240NEW YORK, NY, United States 10118
- Phone
- ---
- Fax
- 302-655-5049
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $74.4M |
|---|---|
Revenue (TTM) | $53.6M |
Shares Outstanding | 99.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-0.59 |
Book Value | $0.91 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -119.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
